{"ticker": {"uuid": "3b024d07-a80f-48f0-bbda-6bb79c593c64", "symbol": "ARWR", "name": "Arrowhead Pharmaceuticals Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Arrowhead Pharmaceuticals (ARWR) Receives EU Approval for REDEMP", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQbDlISHlVOWViNi1nWk1zUUprQ0pkZjNqVENYN3Ytb0dkVXlMWTNCdkp6U0U2c0lmWWlXcFc4b29SM25idHFvWE1hampuN1kwNF9TbTlPVGJIVGhrQnpqd3FFczBET3NvOUM0MVN5eDNWUXhhTTRlcVZQUTNkdW5aZkxRYThyeVFyTVdfbGpnbXlBNXV5eks0bGVrZ0tyMUJaajRFWlJn?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-22T17:25:26+00:00", "published_display": "22 Jun 2026 17:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Reports Marketing Authorization for Redemplo in EU", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/arrowhead-reports-marketing-authorization-redemplo-171006268.html", "source_name": "MT Newswires", "published_at": "2026-06-22T17:10:06+00:00", "published_display": "22 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO\u00ae (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/arrowhead-pharmaceuticals-receives-marketing-authorization-163300060.html", "source_name": "Business Wire", "published_at": "2026-06-22T16:33:00+00:00", "published_display": "22 Jun 2026 16:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EU approves Arrowhead's REDEMPLO for rare fat disorder FCS", "summary": "Arrowhead Pharmaceuticals has received marketing authorization from the European Commission (EC) for REDEMPLO (plozasiran) to treat Familial Chylomicronemia Syndrome (FCS) in adults. This is the first and only siRNA medicine authorized by the EC for FCS that does not require gene", "url": "https://www.stocktitan.net/news/ARWR/arrowhead-pharmaceuticals-receives-marketing-authorization-in-the-im60lb7nbrsx.html", "source_name": "Stock Titan", "published_at": "2026-06-22T16:36:54", "published_display": "22 Jun 2026 16:36", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Pharmaceuticals (ARWR) Stock Could Be 25.6% Undervalued After R And D Webinar Update", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-20T08:02:19+00:00", "published_display": "20 Jun 2026 08:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Are Arrowhead Pharmaceuticals\u2019 (ARWR) Board Moves and RNAi Webinars Quietly Reframing Its Risk Narrative?", "summary": "Arrowhead Pharmaceuticals recently appointed Dr. Matt Cohen to its board and announced an R&D webinar series, highlighting its TRiM-based RNAi pipeline. These moves are seen as strengthening the company's capital markets expertise and increasing visibility for its cardiometabolic", "url": "https://www.sahmcapital.com/news/content/are-arrowhead-pharmaceuticals-arwr-board-moves-and-rnai-webinars-quietly-reframing-its-risk-narrative-2026-06-18", "source_name": "Sahm", "published_at": "2026-06-19T22:40:33", "published_display": "19 Jun 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars", "summary": "Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced it will host a 2026 Summer Series of R&D webinars focusing on its RNA interference (RNAi) based medicines. Part I, scheduled for June 29, 2026, at 11:30 AM EDT, will highlight the company's cardiometabolic pipeline. The webinar w", "url": "https://www.businesswire.com/news/home/20260618080566/en/Arrowhead-Pharmaceuticals-to-Host-a-Webinar-on-its-Cardiometabolic-Pipeline-as-Part-I-of-the-2026-Summer-Series-of-RD-Webinars", "source_name": "Business Wire", "published_at": "2026-06-19T04:10:06", "published_display": "19 Jun 2026 04:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Pharmaceuticals stock hits 52-week high at $82.30", "summary": "Arrowhead Pharmaceuticals Inc. (ARWR) stock reached a new 52-week high of $82.30, trading near its peak with a 394% increase over the past year and a market capitalization of $11.5 billion. Despite this, InvestingPro analysis suggests the stock might be overvalued relative to its", "url": "https://www.investing.com/news/company-news/arrowhead-pharmaceuticals-stock-hits-52week-high-at-8230-93CH-4747979", "source_name": "Investing.com", "published_at": "2026-06-18T15:39:44", "published_display": "18 Jun 2026 15:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead sets June 29 webinar on its cardiometabolic pipeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPdTg0Q1J5WmtnM0JXVlYzdUdjemtwZVdsMVZJeVRYVmxJSFNRNzJHb3NndUtsbUs1T3JQNWlWdFpzVDZGWnVoei1UQzQwTVlFVnVpNlpacVFrZXJWcENQYko0TVlpS0RsLUZEWndvcnJVNGlwOWl2SmpnbWVZT1BNcld5RzQ3UzByWTFpd2wyY1BSc1lTYnZiZ3ZDOE05dGk5c0hWRXlBaXBWUzgwX09Vek4xMnNsaldYX1drRFRR?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T11:30:00+00:00", "published_display": "18 Jun 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Pharmaceuticals Inc", "summary": "The TradingKey platform provides an overview of Arrowhead Pharmaceuticals Inc. (ARWR), including its stock quote, market capitalization, and P/E TTM. However, the article explicitly states that relevant data for revenue breakdown by business segments and regions has not yet been ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-arwr/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T05:09:55", "published_display": "18 Jun 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Pharmaceuticals (ARWR) director files Form 3 showing zero share ownership", "summary": "Arrowhead Pharmaceuticals director Matthew Gregory Cohen has filed an initial Form 3 with the SEC, indicating he currently holds zero shares of the company's Common Stock. This filing serves as a baseline disclosure for him as a newly reported insider and does not represent a buy", "url": "https://www.stocktitan.net/sec-filings/ARWR/form-3-arrowhead-pharmaceuticals-inc-initial-statement-of-beneficial--c18c441cbcf3.html", "source_name": "Stock Titan", "published_at": "2026-06-18T02:09:09", "published_display": "18 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Matthew Cohen granted 11,882 RSUs at Arrowhead Pharmaceuticals (ARWR)", "summary": "Arrowhead Pharmaceuticals director Matthew Gregory Cohen was granted 11,882 Restricted Stock Units (RSUs) on June 15, 2026, at no cash cost. These RSUs will vest over three years, aligning his compensation with the company's long-term performance. Following this grant, Cohen dire", "url": "https://www.stocktitan.net/sec-filings/ARWR/form-4-arrowhead-pharmaceuticals-inc-insider-trading-activity-008a635adfd9.html", "source_name": "Stock Titan", "published_at": "2026-06-18T02:09:09", "published_display": "18 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Pharmaceuticals Rises as Recent Clinical Updates and EU Catalyst Keep Focus on Plozasiran", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxQUGdrWVRYVVVmVi1BaVRwbGNzcVF6bWwtdmtIQlVHNTFnbVY2Sm5rcFJLV1BCZjRNQm9McUtoRWE3QmlKNldtc0ttdllLWmVkOWI4ZWY0UUdKckRfTlhyUWFGMlktYmt5UUVlY1lwYmtCMEx0X2NfaG9iVDVyUGo4Z0o2OHhmZmlaekV0SG5jV3F3bkc2S1ZlWjhIa1NGNkUzZm1fQ1NxcjBfT2phVzhQSlN3cE9Bc05GSjFmcEFuQnJUYUc5MTNRV3J1M0k?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-17T21:21:00+00:00", "published_display": "17 Jun 2026 21:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veteran healthcare investor Matt Cohen joins Arrowhead (ARWR) board with $887K RSU grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPUGt1QXVwaEhKUHl0ZTVVZ3BJNXN2dmtibnlsN0p5MUxESFpoUll6YjFCTnl4ekN5cjVqZEd5Q1Jramdid25kNFo4bUV2NTQ4TVlSUlNhZkg4enlTaDk0OE51WHlKNXNvdF83LXhraVJsLWRZVWltSkV5cGJnNFRoQmF5dHhaYjRiNnJtYXJHQmlWekJrZjU3ckFSU1ZXN2NYdDFsa3dET0JrT0dKQl85eEdQUDdYenQ3VlE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T20:02:56+00:00", "published_display": "16 Jun 2026 20:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Pharmaceuticals Inc (ARWR) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Arrowhead Pharmaceuticals Inc (ARWR) currently holds a financial score of 6.99, ranking 171 out of 388 in the Biotechnology & Medical Research industry, indicating a weak financial status but high operating efficiency. The company reported a significant year-over-year decrease of", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-arwr/financial-health", "source_name": "TradingKey", "published_at": "2026-06-16T19:40:30", "published_display": "16 Jun 2026 19:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Veteran healthcare investor Matt Cohen joins Arrowhead (ARWR) board with $887K RSU grant", "summary": "Arrowhead Pharmaceuticals, Inc. has appointed Dr. Matt Cohen, a veteran healthcare investor with over 25 years of experience, to its Board of Directors, effective June 12, 2026. Dr. Cohen will receive standard non-employee director compensation and a sign-on grant of restricted s", "url": "https://www.stocktitan.net/sec-filings/ARWR/8-k-arrowhead-pharmaceuticals-inc-reports-material-event-60a3271b4bb5.html", "source_name": "Stock Titan", "published_at": "2026-06-16T19:39:22", "published_display": "16 Jun 2026 19:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Arrowhead Pharmaceuticals on the Cusp of a Major Breakout", "summary": "Arrowhead Pharmaceuticals is nearing a critical juncture with Phase 3 data for plozasiran in severe hypertriglyceridemia (SHTG) expected in Q3 2026, which could significantly expand its market beyond familial chylomicronemia syndrome (FCS). The company boasts a strong financial p", "url": "https://www.kavout.com/market-lens/is-arrowhead-pharmaceuticals-on-the-cusp-of-a-major-breakout", "source_name": "Kavout", "published_at": "2026-06-16T03:10:47", "published_display": "16 Jun 2026 03:10", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why (ARWR) Price Action Is Critical for Tactical Trading", "summary": "This article analyzes Arrowhead Pharmaceuticals Inc. (ARWR) with a focus on tactical trading due to divergent sentiment across all horizons. It identifies a mid-channel oscillation pattern and presents three distinct AI-generated trading strategies: Long Position, Momentum Breako", "url": "https://news.stocktradersdaily.com/news_release/35/Why_ARWR_Price_Action_Is_Critical_for_Tactical_Trading_061326075202_1781394722.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-13T20:10:03", "published_display": "13 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha-1 Antitrypsin Deficiency Market to Witness Transformational Growth Opportunities by 2036 \u2013 DelveInsight | Grifols, Kamada Pharma, Takeda, Arrowhead Pharma, Mereo BioPharma, AstraZeneca, Sanofi", "summary": "The Alpha-1 Antitrypsin Deficiency (AATD) market, valued at approximately USD 940 million in 2024 across the 7MM, is projected for significant growth by 2036. This expansion is driven by increasing adoption of approved treatments, advancements in gene therapy and RNA-editing, and", "url": "https://www.barchart.com/story/news/2358259/alpha1-antitrypsin-deficiency-market-to-witness-transformational-growth-opportunities-by-2036-delveinsight-grifols-kamada-pharma-takeda-arrowhead-pharma-mereo-biopharma-astrazeneca-sanofi", "source_name": "Barchart", "published_at": "2026-06-09T11:40:33", "published_display": "09 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Pharmaceuticals, Inc. Trade Ideas \u2014 XETR:HDP1", "summary": "This article compiles several trading ideas and analyses for Arrowhead Pharmaceuticals, Inc. (XETR:HDP1, NASDAQ:ARWR). Contributors discuss various technical patterns such as flag patterns, stair-step patterns, \"cup and handle\" formations, and potential reversals, along with fund", "url": "https://www.tradingview.com/symbols/XETR-HDP1/ideas/page-3/", "source_name": "TradingView", "published_at": "2026-06-07T15:40:33", "published_display": "07 Jun 2026 15:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can Arrowhead Pharmaceuticals (ARWR) Turn RNAi Obesity Ambitions Into a Durable Cardiometabolic Moat?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-07T07:00:00+00:00", "published_display": "07 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Pharmaceuticals (ARWR) Valuation Check After New Plozasiran And ARO-INHBE Clinical Updates", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-06T07:00:00+00:00", "published_display": "06 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Pharmaceuticals Lines Up SHASTA Readout as REDEMPLO Launch Gains Traction", "summary": "Arrowhead Pharmaceuticals is preparing to release topline data for plozasiran (SHASTA-3 and SHASTA-4 studies) in severe hypertriglyceridemia in the third quarter, expressing cautious optimism. The launch of REDEMPLO for familial chylomicronemia syndrome is gaining momentum, showi", "url": "https://finance.yahoo.com/sectors/healthcare/articles/arrowhead-pharmaceuticals-lines-shasta-readout-180329874.html", "source_name": "Market source", "published_at": "2026-06-05T18:09:45", "published_display": "05 Jun 2026 18:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARWR News | ARROWHEAD PHARMACEUTICALS IN (NASDAQ:ARWR)", "summary": "This article provides recent news and analysis for Arrowhead Pharmaceuticals (NASDAQ:ARWR), highlighting its stock performance, recent drug launches, and participation in industry events. It includes financial updates such as strong Q2 earnings, revenue beats, and a report of its", "url": "https://www.chartmill.com/stock/quote/ARWR/news", "source_name": "ChartMill", "published_at": "2026-06-05T11:39:05", "published_display": "05 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events", "summary": "Arrowhead Pharmaceuticals, Inc. announced its participation in two upcoming healthcare conferences in June 2026: the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference. The company will present in fireside chats at both events, w", "url": "https://www.businesswire.com/news/home/20260602573089/en/Arrowhead-Pharmaceuticals-to-Participate-in-Upcoming-June-2026-Events", "source_name": "Business Wire", "published_at": "2026-06-03T09:10:35", "published_display": "03 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Pharmaceuticals Drops 7.0% Amid Sector-Wide Selling", "summary": "Arrowhead Pharmaceuticals (ARWR) saw its stock price drop by 7.0% on Tuesday, closing at $69.95, as the biotechnology sector experienced a broad selloff. This decline was part of a wider downdraft affecting several peer companies, indicating a sector-wide investor rotation rather", "url": "https://news.alphastreet.com/arrowhead-pharmaceuticals-drops-7-0-amid-sector-wide-selling/", "source_name": "AlphaStreet", "published_at": "2026-06-02T14:39:21", "published_display": "02 Jun 2026 14:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Pharmaceuticals eyes Q3 SHASTA data as REDEMPLO approvals build momentum", "summary": "Arrowhead Pharmaceuticals is anticipating Q3 data from its SHASTA trial. This comes as approvals for its drug REDEMPLO are gaining momentum. The company is focused on advancing its pipeline with these key developments.", "url": "https://www.msn.com/en-us/health/other/arrowhead-pharmaceuticals-eyes-q3-shasta-data-as-redemplo-approvals-build-momentum/ar-AA23Fjhe", "source_name": "MSN", "published_at": "2026-06-01T07:09:32", "published_display": "01 Jun 2026 07:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After New Plozasiran And ARO INHBE Clinical Results", "summary": "Arrowhead Pharmaceuticals, Inc. (ARWR) is gaining investor attention due to positive clinical data for plozasiran and ARO-INHBE, leading to a significant increase in its share price. While one market narrative suggests the stock is 23.3% overvalued with a fair value of $64.08, a ", "url": "https://www.sahmcapital.com/news/content/assessing-arrowhead-pharmaceuticals-arwr-valuation-after-new-plozasiran-and-aro-inhbe-clinical-results-2026-05-28", "source_name": "Sahm", "published_at": "2026-05-30T09:21:51", "published_display": "30 May 2026 09:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026", "summary": "Arrowhead Pharmaceuticals presented new interim results from a Phase 1/2a clinical trial of ARO-INHBE, an RNAi therapeutic for obesity and MASH, at EASL 2026. The data show that ARO-INHBE significantly reduced liver fat as both a monotherapy and in combination with low-dose tirze", "url": "https://www.businesswire.com/news/home/20260527903149/en/Arrowhead-Pharmaceuticals-Presents-New-Clinical-Data-on-RNAi-based-Obesity-and-MASH-Candidate-ARO-INHBE-at-EASL-2026", "source_name": "Business Wire", "published_at": "2026-05-27T18:09:10", "published_display": "27 May 2026 18:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress", "summary": "Arrowhead Pharmaceuticals shared new clinical data for plozasiran at the 94th European Atherosclerosis Society Congress, demonstrating its potential use in patients with moderate-to-severe renal or moderate hepatic impairment without dose adjustment. The data also included a case", "url": "https://www.businesswire.com/news/home/20260526998701/en/Arrowhead-Pharmaceuticals-Presents-New-Positive-Clinical-Cardiometabolic-Data-at-the-94th-European-Atherosclerosis-Society-EAS-Congress", "source_name": "Business Wire", "published_at": "2026-05-27T06:10:08", "published_display": "27 May 2026 06:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bernstein Lifts PT on Arrowhead Pharmaceuticals (ARWR) Following Biotech\u2019s Solid Start to 2026", "summary": "Bernstein has increased its price target for Arrowhead Pharmaceuticals (ARWR) to $46 from $35, while maintaining a Market Perform rating. This adjustment follows a strong start to 2026 for the biotech sector, with ARWR outperforming the market. The company also reported positive ", "url": "https://www.insidermonkey.com/blog/bernstein-lifts-pt-on-arrowhead-pharmaceuticals-arwr-following-biotechs-solid-start-to-2026-1768629/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-05-27T06:10:08", "published_display": "27 May 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Data On Plozasiran Expands Cardiometabolic Opportunity And Investor Focus", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/arrowhead-data-plozasiran-expands-cardiometabolic-191602429.html", "source_name": "Simply Wall St.", "published_at": "2026-05-26T19:16:02+00:00", "published_display": "26 May 2026 19:16", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARWR - Analysts Boost Arrowhead Pharmaceuticals Price Target Amid Cost Advantages and Strategic Partnerships", "summary": "Analysts have increased their price targets for Arrowhead Pharmaceuticals ($ARWR) due to the FDA approval of Redemplo, a stronger commercial outlook for familial chylomicronemia syndrome and severe hypertriglyceridemia (sHTG), and long-term cost and margin advantages. While bulli", "url": "https://simplywall.st/narratives/4en276wc-analysts-boost-arrowhead-pharmaceuticals-price-target-amid-cost-advantages-and-strategic-partnerships?bpId=4485619&link_type=cta_ai_narrative", "source_name": "Simply Wall Street", "published_at": "2026-05-26T18:09:10", "published_display": "26 May 2026 18:09", "sentiment": "positive", "sentiment_pct": 77, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Hongbo Lu notifies sale of 2,970 ARWR shares (NASDAQ: ARWR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQZkVOanRGdEFOR3VQWEV2X1cyMDFaV19ncVBVdEhic1FGUExsTk11SjdIUGQ1XzgwVURUWkNZY0psMEVpdndiZFN4dHFaMGk3cGZObU0zbEQ2Q2UwV2VETE1UM3pza3VPVHAyTVFIcno0OUtncEh3N1lzOWZWMjhQOEJIT003bThNZTdzVGFKNVp4THFPQnVZLWdUWjREcU9TMW1hbXQ2Tml6eDZt?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Licenses ARO PNPLA3 To Madrigal To Expand MASH Options", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxOcm5lOTM5YUlicnViYUlERkxkMnZRTWl0d2F1ZWVWVTFOM0xRbjJsT0hDMVc2WnFwTTFJUW9DZWdWN1lOQkgxWFhBa1kwZHc3QzVVOTkxU09YMDV6cGIzOFA3YWlZLVk3ZjViQ2oySzlyRzE0S20zTWptY0k2Qy1UNEh5Z18xM3JmaW9hYzNVQS1janpYVFpQdWVqZjFzSTJlSkVNeE1xU191TE5UNkVHLWdsME56UFBYaDA1clZtTy1ldVl2TURPS0NscUVEQzduT2ZEOEYyNXpRZERzOGlpbkJldlJJVVNOVXp2Nm9CTG_SAfYBQVVfeXFMT1RaN2dkNE1nUlRxRTJ1ZlZpNldReG1hVHIydFJtdm1nVElWZXQ5cnp6TGxfeTJQb3VTMGRmbXJaOUczSnFnbEJObjdvNHRkR2NCV2ZWMThDLXo4RGVueVEyczVNeFk2ODZwSlRKWmFOekx0RkhpZG01RHFGdm5YSFZ2djF3NUF3S0VRZ0dCdE1rbU5tdHVaLTdJa0NjQVZuYWhQYmpHUml5cVc3MV95c0RHWmM1bHpZVUczalNELURDeWRfWFVlZ0ZsMFlocVhxZ0xOR0FhT1BtS3pVazltcFE3YWJZQ3lfZlVzYnZmWnVDa3Bzamt3?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Arrowhead (NASDAQ: ARWR) director sells 2,970 shares under Rule 10b5-1 plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOeV94eUZ3eFVUMzVfUHY1Z1g0YW5RVUp6aDRScXliSVVqUTUwZERnbDg3VkNub3REX2dFZ0RFQ0V6Q3c1WkNRYVo5VWRzMzlJSG8yaWxERlNSbDFEZWcwdmFvNFE3bno2T2xvaWVlY2x3NXVOU1lqZ1B6Q3U1LWRGblNDZWxOWkEyYmxEaU5rSXIzZlZ0cy11VElsQ1p1b2tPaWprT3J6b2s0MUhZMG52Y2pqREtkZG5ub2lpaWxiREI?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "[144] ARROWHEAD PHARMACEUTICALS, INC. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQNlRGVE13NG5mUUw3YzBTUDM0UF9HcEtlSFBOOHlEcGdXYXVmQmQzNnFxS0p2MzV4Yy14UldLVDBBMVFTeEtXQ3dNOVBlS3NzTTBaS1o1ZUFxdlZCZnVzVU1XR2dsd3QtYTFQOUZjVDFncktfRnRfaTh3clIxbVdZQm1WZUFuanFCMHBFNlQ2SkNSRHlCZlVCMk56aUpEaVRGczVXX2hEb2pXQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After Its Recent Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOaTUzV3F5MFJPU2owN1VFR0MtcHYzaHVrVjFhYmlnLTJvNFdCVkYzaHBSdXpycENXY1gxODVwY1EzTXpkekF3U2pYTmxxd2Z1Y2dFUlJobDVLTmZvVkVxRFNVSUZGRnZ3THBDclpwajg3UXNvNzhZdXpvZXVnR2xQdkdVTEVLMEU5WXpHNDNLcWs0Q2ZGLUpkbjk1SXI?oc=5", "source_name": "Market source", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Has Arrowhead Pharmaceuticals (ARWR) Run Too Far After Its 488% One Year Surge", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxQZmhJaUt5NFZnZEUweGZObl80UkozYUw0T2JfQzlTa2d1RE5icTMzYWYtV3VyZzR4OG5oRzlWN1NRMjRJSUVVSXBBTjdsVUs2NW5RMUgxbDVTc3JkYU45TVQyaWJmT2hnQUFrM3cxWHNVNHJkYi1tUzlVZ2lKczBqYzhqT1c2ZlNtRi1qUmc3a2R5eW52N3h5MTRPNGN3TzNsTm9rdHNjSkQ2Q0UwbUNYSFh0RFdoSTl5QmhEU2xnd3JpYWlDa2h4YXVHelhLcmJ1QU5kTHdQTVhsQkNfbUJuV29hWXc4RU9tNW9vZDd1aU_SAfYBQVVfeXFMTkpsaHNfTEhBZmdqdkhvVTZDVEh4cWpicU5XQ3hCRGRtYy13aVhzdkwxRDNZS3lPbHQ2MjNvQW1jWk92MTkyOHIzeGdpNVpCMDdBaXFiMjhKX25ZcC1Ib3RKUTdqenM4LW5xclVJU3p3ZUtGV3ZrSnNnYXY5YjdpRTRmMGxsZVVLbzNWcnp1c09OSGp6TDBDMVJhU3ZROU56Tzg4dmFtVm9iQVFFck1LOEVHTGk3X1lpbjc4N3lVV1BEMVVpalVUWHB5TEFYc0RxLXAxdjJSbDl6Y3ZaeXJ1YmdQUjVOM2NSd2t3bFRXVEF1akZmczJR?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Pharmaceuticals (ARWR) Q1 Profit Supports Bullish Narrative Despite High 54x P/E", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARROWHEAD PHARMACEUTICALS ($ARWR) Releases Q2 2026 Earnings | ARWR Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxPUnlCako4MUR3em9WdHg5Z2lzcUx2VlNXUVhHX1o2bGJmUHlFTXN5Y2JlSUN3em05STNkX0pINFpzZTlFanoxS244STRQS18xWkhVMGVPZGJLLWIyRFVCTzhDV09yRXg1dHk1NzFabVoxZ04waU96RDBBQlVrN0Q0WVY5cnNrZkcxbFVHakFXaDdFWjRqdVNV?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan Expects Arrowhead Pharma Stock to Rally on RNAi Portfolio Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNLU0zeUVEOWJDRjB2YS1wdkdKYU1Iczd3MUVNTGdoMGh6ZVQwRnp0N2JBYVVqZnRwaU1KQWN4VGozQWRyZldwTVRpdWZjbVlISE1za0FvNHo1MVhMQnVuNVBIWEZ1MEt2T3RjYnFDckw0REU5SXI1OWpMbHZkWjhhWW9aZFE0NnJST3VLNFVNaFhMaVV0d1ExTVFHd1RtNHUt?oc=5", "source_name": "TIKR.com", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "After 46% liver fat cut, Madrigal licenses Arrowhead MASH drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNOTFfWVJueGNSXzZ0SkZoTnV5a0FOVFJ5VG5HWWZtdjBaVXMzeWV4RTVzNUw0Z0dNZHpxUlVhNWdQZ0c2UVJRclRSMnhud20yNGM3UURZWTh6bkJUZjlNN05VZ2xZTTcwUERaQ1FfajF4S0pkQWs1dDZPX244cldGMlNkV3RYWkdiNEZmc1pXX2xYZW9aTFBzNExBNGN3VjgzVlJOb1ZfTjIteGRCamdDRmVFVmRWZnlDTmlJNWlB?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead lines up six May talks on obesity, liver fat and tau", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOSWdiamJmYVFna1pGTlZpakZQckxZMVp5c2VvWW5iZnFQYnZlbkN3cEhCVGpsSEhvY0p2VG9pcDdVdExTVi1vYmY1TTRiZnhZNEoyeVBISmg4V2VTNmVyaUkwNk5tX1RkaVFGNjFrMy1OSzVZS01qZGVPdjhyc19pSG56dGxYeGdqOUlrUmE0enlOdlpwa19odVBLbVJyTmN5T1FFVWlrdDFOX2NTQ2hhNVR0Sk5uVFE?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanguard Portfolio Management (NASDAQ: ARWR) reports 5.19% stake in Arrowhead", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNNjRGMk80YkRDQkU0cGpsUEF0SFFOM3RiZVhDMHRDV05XcDhmTzZDeldtOWVmMnM5VUctbXRiNzlNTXB1b2ZBVHE2SVNTSmRXaXV5TEExRFZaWnZ0cXYxb19tNklralFfUWZfOUZUM2JUYlh3Q005Y21IR0xDd3JRUHdkOXZKLXRrNFM2Uk5pYmM1UW9MT0VDY2Jra3pUd0FRU2ppa3psRTFEZzJtaHpnMXpiSndOci1rRTA5MjBPMDh6RC1hUVhyNHRhbw?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Arrowhead Pharmaceuticals: Transition Phase With Moderate Upside Ahead (NASDAQ:ARWR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQcS13SHFQbWtWUW50bDIxZDFGM01uUFdWc2VrQmZrVzZhdERSZmZhdGNGd0QxemM4OHh5cENoaGxqNnpxTEtsUF83cTUxaTl1VzZiV3daeUxlbUx1UU81T0V0NS1VRjBaOXhTdTN2MVNJeWh1RkRBRVBfYlZHN2lEMzlTZ1VWSXdyRTlHOEYwV3BpNGd2S1hWUTBVWTZsSGhQVlgyVURxaFZfT2c0Sm5z?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Pharmaceuticals Inc. (ARWR): Billionaire Ken Fisher Bets Big on Pharma", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxPUGg2VGk3aWxfc1pVMUR1ejJvcUFLa0lDYjVDRllwd2RUalRFVFBYTjNJUXJPMDVQLW91ZmdzR05DR01IQmoxakJOR3E4RER1RThpX2E4U2VRWmFPNGttR3NlODBwaUJPLVkzamtSNUxLQTR5WUV1aGgyQWx0eE9ka1NFNlJEWUdTaER6NE5UUl9IOWp0cHdR?oc=5", "source_name": "Market source", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Strong Earnings Are Of Good Quality", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Have Arrowhead Pharmaceuticals Insiders Been Selling Stock?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-03T08:00:00+00:00", "published_display": "03 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock Catapults 33% Though Its Price And Business Still Lag The Industry", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-02T08:00:00+00:00", "published_display": "02 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US FDA approves Arrowhead's genetic disorder drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPVGdKY0R4Y1BtY3JPYkxNUTdMZW01WF9rUVNId3dEbGxpWmF1ZXc5ZkJUOURUQTlXTEpaMDVoeXRnMzdNdnV6QUdHUnBUZmU3cTYtMUcwbmNqQXRFUVRqbGFDdzgzWTVPaXhoaHg1eFh2RFdmVVJ5VW9KZW42VGMtZUxTSUtqRHpMUVllM0VJOUhncTNERHo4THVHLTc4R3Yyc19aYi1rMkpmaVBIcTJTcnJaWTlSQVAzZ0p1Mw?oc=5", "source_name": "Reuters", "published_at": "2025-11-18T08:00:00+00:00", "published_display": "18 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Therapeutics Announces Advancement of siRNA Collaboration and Sale of Arrowhead Equity Investment", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxPemRoWUduMVZ2eGVVSUtnUjhQQUJfMm82WUtoQUJ4R2ZsMUtKbi1GdnlGbXpYaHgtaUhsOTBSVHRxLUdzM0xkRkN4d2pYMlNhUFdrcFdXUTB5UTB0ZERQY1A1VDI5VVdia2xHTEQ4MV9NeHQyd202alJOblBOUTZaLVYxbnE2cldvdm5hX2ZiMG90UVBXLWlTRVdaenpseTJEcmVSMnd5YUtlMnpsYVphZ2l1bEVVeGdjRGVCd1hVa2NUSW5Vczl4QjR2T09rRUJS?oc=5", "source_name": "Sarepta Therapeutics", "published_at": "2025-08-13T07:00:00+00:00", "published_display": "13 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Arrowhead Pharmaceuticals (ARWR) Receives EU Approval for REDEMP", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQbDlISHlVOWViNi1nWk1zUUprQ0pkZjNqVENYN3Ytb0dkVXlMWTNCdkp6U0U2c0lmWWlXcFc4b29SM25idHFvWE1hampuN1kwNF9TbTlPVGJIVGhrQnpqd3FFczBET3NvOUM0MVN5eDNWUXhhTTRlcVZQUTNkdW5aZkxRYThyeVFyTVdfbGpnbXlBNXV5eks0bGVrZ0tyMUJaajRFWlJn?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-22T17:25:26+00:00", "published_display": "22 Jun 2026 17:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Reports Marketing Authorization for Redemplo in EU", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/arrowhead-reports-marketing-authorization-redemplo-171006268.html", "source_name": "MT Newswires", "published_at": "2026-06-22T17:10:06+00:00", "published_display": "22 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO\u00ae (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/arrowhead-pharmaceuticals-receives-marketing-authorization-163300060.html", "source_name": "Business Wire", "published_at": "2026-06-22T16:33:00+00:00", "published_display": "22 Jun 2026 16:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EU approves Arrowhead's REDEMPLO for rare fat disorder FCS", "summary": "Arrowhead Pharmaceuticals has received marketing authorization from the European Commission (EC) for REDEMPLO (plozasiran) to treat Familial Chylomicronemia Syndrome (FCS) in adults. This is the first and only siRNA medicine authorized by the EC for FCS that does not require gene", "url": "https://www.stocktitan.net/news/ARWR/arrowhead-pharmaceuticals-receives-marketing-authorization-in-the-im60lb7nbrsx.html", "source_name": "Stock Titan", "published_at": "2026-06-22T16:36:54", "published_display": "22 Jun 2026 16:36", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Pharmaceuticals (ARWR) Stock Could Be 25.6% Undervalued After R And D Webinar Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxNNG1NUnhLZXZ2akMyaGVLdTZoU0ZyRFN6MjlWckcxdjhXSHdVaGxFNU5SR3FnX2NpN3oxME5UTG04ZFRNRDloQTdVNDBnWGItLTVhMktYOEN0U085a2lTNHR1NmZfRjZpSWtXMG9lOTFleENjQ2g0WXJvalFFSVpvMW1uNWs0ZEs0NFN6SFVxMGdlbnpPNFpVWE5VWnVobzBzWGNpamJESmNrb1NVVTZMa0FrSkZoLU44djVQMVBaR0VnMl9jdGdieEZoS3EwN2x0bzZDcFlFd0E5eWNQUDdWeXczQXNqVlcyM202SFJ5WmjSAfYBQVVfeXFMTXZ5bjQxVzhZUlR6MFdiQTUybm1wdnA0TXhDNVlXckNpV09zRmJDM3JLSDhVTmgyVWdQY3VnMXlUTkhoMlYxS3ZKd3ozZWNVaHhGRW5QNEtxbExWNzRGLXdEcWVOd0ZVdG1RMTAtYlFRYkFteTNzc2xHZlJXbEd5SDF5T01aQmZFQWdjeFlfS1p6UDM3bnRUOTNacE9EVlFfQnp6ODFDdUZqT2RrNFZiLU5Ba3M4YUJrOXJQOU1hN003ZnhZZ085OEhKRzJSTC1jbEZweGxFTnpwZk9fMXJjTGZ0YTNibTRBSjJYWG9YMW9YRmxLNkF3?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-20T08:02:19+00:00", "published_display": "20 Jun 2026 08:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Are Arrowhead Pharmaceuticals\u2019 (ARWR) Board Moves and RNAi Webinars Quietly Reframing Its Risk Narrative?", "summary": "Arrowhead Pharmaceuticals recently appointed Dr. Matt Cohen to its board and announced an R&D webinar series, highlighting its TRiM-based RNAi pipeline. These moves are seen as strengthening the company's capital markets expertise and increasing visibility for its cardiometabolic", "url": "https://www.sahmcapital.com/news/content/are-arrowhead-pharmaceuticals-arwr-board-moves-and-rnai-webinars-quietly-reframing-its-risk-narrative-2026-06-18", "source_name": "Sahm", "published_at": "2026-06-19T22:40:33", "published_display": "19 Jun 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars", "summary": "Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced it will host a 2026 Summer Series of R&D webinars focusing on its RNA interference (RNAi) based medicines. Part I, scheduled for June 29, 2026, at 11:30 AM EDT, will highlight the company's cardiometabolic pipeline. The webinar w", "url": "https://www.businesswire.com/news/home/20260618080566/en/Arrowhead-Pharmaceuticals-to-Host-a-Webinar-on-its-Cardiometabolic-Pipeline-as-Part-I-of-the-2026-Summer-Series-of-RD-Webinars", "source_name": "Business Wire", "published_at": "2026-06-19T04:10:06", "published_display": "19 Jun 2026 04:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Pharmaceuticals stock hits 52-week high at $82.30", "summary": "Arrowhead Pharmaceuticals Inc. (ARWR) stock reached a new 52-week high of $82.30, trading near its peak with a 394% increase over the past year and a market capitalization of $11.5 billion. Despite this, InvestingPro analysis suggests the stock might be overvalued relative to its", "url": "https://www.investing.com/news/company-news/arrowhead-pharmaceuticals-stock-hits-52week-high-at-8230-93CH-4747979", "source_name": "Investing.com", "published_at": "2026-06-18T15:39:44", "published_display": "18 Jun 2026 15:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead sets June 29 webinar on its cardiometabolic pipeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPdTg0Q1J5WmtnM0JXVlYzdUdjemtwZVdsMVZJeVRYVmxJSFNRNzJHb3NndUtsbUs1T3JQNWlWdFpzVDZGWnVoei1UQzQwTVlFVnVpNlpacVFrZXJWcENQYko0TVlpS0RsLUZEWndvcnJVNGlwOWl2SmpnbWVZT1BNcld5RzQ3UzByWTFpd2wyY1BSc1lTYnZiZ3ZDOE05dGk5c0hWRXlBaXBWUzgwX09Vek4xMnNsaldYX1drRFRR?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T11:30:00+00:00", "published_display": "18 Jun 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Pharmaceuticals Inc", "summary": "The TradingKey platform provides an overview of Arrowhead Pharmaceuticals Inc. (ARWR), including its stock quote, market capitalization, and P/E TTM. However, the article explicitly states that relevant data for revenue breakdown by business segments and regions has not yet been ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-arwr/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T05:09:55", "published_display": "18 Jun 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Pharmaceuticals (ARWR) director files Form 3 showing zero share ownership", "summary": "Arrowhead Pharmaceuticals director Matthew Gregory Cohen has filed an initial Form 3 with the SEC, indicating he currently holds zero shares of the company's Common Stock. This filing serves as a baseline disclosure for him as a newly reported insider and does not represent a buy", "url": "https://www.stocktitan.net/sec-filings/ARWR/form-3-arrowhead-pharmaceuticals-inc-initial-statement-of-beneficial--c18c441cbcf3.html", "source_name": "Stock Titan", "published_at": "2026-06-18T02:09:09", "published_display": "18 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Matthew Cohen granted 11,882 RSUs at Arrowhead Pharmaceuticals (ARWR)", "summary": "Arrowhead Pharmaceuticals director Matthew Gregory Cohen was granted 11,882 Restricted Stock Units (RSUs) on June 15, 2026, at no cash cost. These RSUs will vest over three years, aligning his compensation with the company's long-term performance. Following this grant, Cohen dire", "url": "https://www.stocktitan.net/sec-filings/ARWR/form-4-arrowhead-pharmaceuticals-inc-insider-trading-activity-008a635adfd9.html", "source_name": "Stock Titan", "published_at": "2026-06-18T02:09:09", "published_display": "18 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Pharmaceuticals Rises as Recent Clinical Updates and EU Catalyst Keep Focus on Plozasiran", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxQUGdrWVRYVVVmVi1BaVRwbGNzcVF6bWwtdmtIQlVHNTFnbVY2Sm5rcFJLV1BCZjRNQm9McUtoRWE3QmlKNldtc0ttdllLWmVkOWI4ZWY0UUdKckRfTlhyUWFGMlktYmt5UUVlY1lwYmtCMEx0X2NfaG9iVDVyUGo4Z0o2OHhmZmlaekV0SG5jV3F3bkc2S1ZlWjhIa1NGNkUzZm1fQ1NxcjBfT2phVzhQSlN3cE9Bc05GSjFmcEFuQnJUYUc5MTNRV3J1M0k?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-17T21:21:00+00:00", "published_display": "17 Jun 2026 21:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veteran healthcare investor Matt Cohen joins Arrowhead (ARWR) board with $887K RSU grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPUGt1QXVwaEhKUHl0ZTVVZ3BJNXN2dmtibnlsN0p5MUxESFpoUll6YjFCTnl4ekN5cjVqZEd5Q1Jramdid25kNFo4bUV2NTQ4TVlSUlNhZkg4enlTaDk0OE51WHlKNXNvdF83LXhraVJsLWRZVWltSkV5cGJnNFRoQmF5dHhaYjRiNnJtYXJHQmlWekJrZjU3ckFSU1ZXN2NYdDFsa3dET0JrT0dKQl85eEdQUDdYenQ3VlE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T20:02:56+00:00", "published_display": "16 Jun 2026 20:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Pharmaceuticals Inc (ARWR) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Arrowhead Pharmaceuticals Inc (ARWR) currently holds a financial score of 6.99, ranking 171 out of 388 in the Biotechnology & Medical Research industry, indicating a weak financial status but high operating efficiency. The company reported a significant year-over-year decrease of", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-arwr/financial-health", "source_name": "TradingKey", "published_at": "2026-06-16T19:40:30", "published_display": "16 Jun 2026 19:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Veteran healthcare investor Matt Cohen joins Arrowhead (ARWR) board with $887K RSU grant", "summary": "Arrowhead Pharmaceuticals, Inc. has appointed Dr. Matt Cohen, a veteran healthcare investor with over 25 years of experience, to its Board of Directors, effective June 12, 2026. Dr. Cohen will receive standard non-employee director compensation and a sign-on grant of restricted s", "url": "https://www.stocktitan.net/sec-filings/ARWR/8-k-arrowhead-pharmaceuticals-inc-reports-material-event-60a3271b4bb5.html", "source_name": "Stock Titan", "published_at": "2026-06-16T19:39:22", "published_display": "16 Jun 2026 19:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Arrowhead Pharmaceuticals on the Cusp of a Major Breakout", "summary": "Arrowhead Pharmaceuticals is nearing a critical juncture with Phase 3 data for plozasiran in severe hypertriglyceridemia (SHTG) expected in Q3 2026, which could significantly expand its market beyond familial chylomicronemia syndrome (FCS). The company boasts a strong financial p", "url": "https://www.kavout.com/market-lens/is-arrowhead-pharmaceuticals-on-the-cusp-of-a-major-breakout", "source_name": "Kavout", "published_at": "2026-06-16T03:10:47", "published_display": "16 Jun 2026 03:10", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why (ARWR) Price Action Is Critical for Tactical Trading", "summary": "This article analyzes Arrowhead Pharmaceuticals Inc. (ARWR) with a focus on tactical trading due to divergent sentiment across all horizons. It identifies a mid-channel oscillation pattern and presents three distinct AI-generated trading strategies: Long Position, Momentum Breako", "url": "https://news.stocktradersdaily.com/news_release/35/Why_ARWR_Price_Action_Is_Critical_for_Tactical_Trading_061326075202_1781394722.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-13T20:10:03", "published_display": "13 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alpha-1 Antitrypsin Deficiency Market to Witness Transformational Growth Opportunities by 2036 \u2013 DelveInsight | Grifols, Kamada Pharma, Takeda, Arrowhead Pharma, Mereo BioPharma, AstraZeneca, Sanofi", "summary": "The Alpha-1 Antitrypsin Deficiency (AATD) market, valued at approximately USD 940 million in 2024 across the 7MM, is projected for significant growth by 2036. This expansion is driven by increasing adoption of approved treatments, advancements in gene therapy and RNA-editing, and", "url": "https://www.barchart.com/story/news/2358259/alpha1-antitrypsin-deficiency-market-to-witness-transformational-growth-opportunities-by-2036-delveinsight-grifols-kamada-pharma-takeda-arrowhead-pharma-mereo-biopharma-astrazeneca-sanofi", "source_name": "Barchart", "published_at": "2026-06-09T11:40:33", "published_display": "09 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Pharmaceuticals, Inc. Trade Ideas \u2014 XETR:HDP1", "summary": "This article compiles several trading ideas and analyses for Arrowhead Pharmaceuticals, Inc. (XETR:HDP1, NASDAQ:ARWR). Contributors discuss various technical patterns such as flag patterns, stair-step patterns, \"cup and handle\" formations, and potential reversals, along with fund", "url": "https://www.tradingview.com/symbols/XETR-HDP1/ideas/page-3/", "source_name": "TradingView", "published_at": "2026-06-07T15:40:33", "published_display": "07 Jun 2026 15:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can Arrowhead Pharmaceuticals (ARWR) Turn RNAi Obesity Ambitions Into a Durable Cardiometabolic Moat?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-07T07:00:00+00:00", "published_display": "07 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Pharmaceuticals (ARWR) Valuation Check After New Plozasiran And ARO-INHBE Clinical Updates", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-06T07:00:00+00:00", "published_display": "06 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Pharmaceuticals Lines Up SHASTA Readout as REDEMPLO Launch Gains Traction", "summary": "Arrowhead Pharmaceuticals is preparing to release topline data for plozasiran (SHASTA-3 and SHASTA-4 studies) in severe hypertriglyceridemia in the third quarter, expressing cautious optimism. The launch of REDEMPLO for familial chylomicronemia syndrome is gaining momentum, showi", "url": "https://finance.yahoo.com/sectors/healthcare/articles/arrowhead-pharmaceuticals-lines-shasta-readout-180329874.html", "source_name": "Market source", "published_at": "2026-06-05T18:09:45", "published_display": "05 Jun 2026 18:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARWR News | ARROWHEAD PHARMACEUTICALS IN (NASDAQ:ARWR)", "summary": "This article provides recent news and analysis for Arrowhead Pharmaceuticals (NASDAQ:ARWR), highlighting its stock performance, recent drug launches, and participation in industry events. It includes financial updates such as strong Q2 earnings, revenue beats, and a report of its", "url": "https://www.chartmill.com/stock/quote/ARWR/news", "source_name": "ChartMill", "published_at": "2026-06-05T11:39:05", "published_display": "05 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events", "summary": "Arrowhead Pharmaceuticals, Inc. announced its participation in two upcoming healthcare conferences in June 2026: the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference. The company will present in fireside chats at both events, w", "url": "https://www.businesswire.com/news/home/20260602573089/en/Arrowhead-Pharmaceuticals-to-Participate-in-Upcoming-June-2026-Events", "source_name": "Business Wire", "published_at": "2026-06-03T09:10:35", "published_display": "03 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Pharmaceuticals Drops 7.0% Amid Sector-Wide Selling", "summary": "Arrowhead Pharmaceuticals (ARWR) saw its stock price drop by 7.0% on Tuesday, closing at $69.95, as the biotechnology sector experienced a broad selloff. This decline was part of a wider downdraft affecting several peer companies, indicating a sector-wide investor rotation rather", "url": "https://news.alphastreet.com/arrowhead-pharmaceuticals-drops-7-0-amid-sector-wide-selling/", "source_name": "AlphaStreet", "published_at": "2026-06-02T14:39:21", "published_display": "02 Jun 2026 14:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Pharmaceuticals eyes Q3 SHASTA data as REDEMPLO approvals build momentum", "summary": "Arrowhead Pharmaceuticals is anticipating Q3 data from its SHASTA trial. This comes as approvals for its drug REDEMPLO are gaining momentum. The company is focused on advancing its pipeline with these key developments.", "url": "https://www.msn.com/en-us/health/other/arrowhead-pharmaceuticals-eyes-q3-shasta-data-as-redemplo-approvals-build-momentum/ar-AA23Fjhe", "source_name": "MSN", "published_at": "2026-06-01T07:09:32", "published_display": "01 Jun 2026 07:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After New Plozasiran And ARO INHBE Clinical Results", "summary": "Arrowhead Pharmaceuticals, Inc. (ARWR) is gaining investor attention due to positive clinical data for plozasiran and ARO-INHBE, leading to a significant increase in its share price. While one market narrative suggests the stock is 23.3% overvalued with a fair value of $64.08, a ", "url": "https://www.sahmcapital.com/news/content/assessing-arrowhead-pharmaceuticals-arwr-valuation-after-new-plozasiran-and-aro-inhbe-clinical-results-2026-05-28", "source_name": "Sahm", "published_at": "2026-05-30T09:21:51", "published_display": "30 May 2026 09:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026", "summary": "Arrowhead Pharmaceuticals presented new interim results from a Phase 1/2a clinical trial of ARO-INHBE, an RNAi therapeutic for obesity and MASH, at EASL 2026. The data show that ARO-INHBE significantly reduced liver fat as both a monotherapy and in combination with low-dose tirze", "url": "https://www.businesswire.com/news/home/20260527903149/en/Arrowhead-Pharmaceuticals-Presents-New-Clinical-Data-on-RNAi-based-Obesity-and-MASH-Candidate-ARO-INHBE-at-EASL-2026", "source_name": "Business Wire", "published_at": "2026-05-27T18:09:10", "published_display": "27 May 2026 18:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress", "summary": "Arrowhead Pharmaceuticals shared new clinical data for plozasiran at the 94th European Atherosclerosis Society Congress, demonstrating its potential use in patients with moderate-to-severe renal or moderate hepatic impairment without dose adjustment. The data also included a case", "url": "https://www.businesswire.com/news/home/20260526998701/en/Arrowhead-Pharmaceuticals-Presents-New-Positive-Clinical-Cardiometabolic-Data-at-the-94th-European-Atherosclerosis-Society-EAS-Congress", "source_name": "Business Wire", "published_at": "2026-05-27T06:10:08", "published_display": "27 May 2026 06:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bernstein Lifts PT on Arrowhead Pharmaceuticals (ARWR) Following Biotech\u2019s Solid Start to 2026", "summary": "Bernstein has increased its price target for Arrowhead Pharmaceuticals (ARWR) to $46 from $35, while maintaining a Market Perform rating. This adjustment follows a strong start to 2026 for the biotech sector, with ARWR outperforming the market. The company also reported positive ", "url": "https://www.insidermonkey.com/blog/bernstein-lifts-pt-on-arrowhead-pharmaceuticals-arwr-following-biotechs-solid-start-to-2026-1768629/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-05-27T06:10:08", "published_display": "27 May 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Data On Plozasiran Expands Cardiometabolic Opportunity And Investor Focus", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/arrowhead-data-plozasiran-expands-cardiometabolic-191602429.html", "source_name": "Simply Wall St.", "published_at": "2026-05-26T19:16:02+00:00", "published_display": "26 May 2026 19:16", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARWR - Analysts Boost Arrowhead Pharmaceuticals Price Target Amid Cost Advantages and Strategic Partnerships", "summary": "Analysts have increased their price targets for Arrowhead Pharmaceuticals ($ARWR) due to the FDA approval of Redemplo, a stronger commercial outlook for familial chylomicronemia syndrome and severe hypertriglyceridemia (sHTG), and long-term cost and margin advantages. While bulli", "url": "https://simplywall.st/narratives/4en276wc-analysts-boost-arrowhead-pharmaceuticals-price-target-amid-cost-advantages-and-strategic-partnerships?bpId=4485619&link_type=cta_ai_narrative", "source_name": "Simply Wall Street", "published_at": "2026-05-26T18:09:10", "published_display": "26 May 2026 18:09", "sentiment": "positive", "sentiment_pct": 77, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Hongbo Lu notifies sale of 2,970 ARWR shares (NASDAQ: ARWR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQZkVOanRGdEFOR3VQWEV2X1cyMDFaV19ncVBVdEhic1FGUExsTk11SjdIUGQ1XzgwVURUWkNZY0psMEVpdndiZFN4dHFaMGk3cGZObU0zbEQ2Q2UwV2VETE1UM3pza3VPVHAyTVFIcno0OUtncEh3N1lzOWZWMjhQOEJIT003bThNZTdzVGFKNVp4THFPQnVZLWdUWjREcU9TMW1hbXQ2Tml6eDZt?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Licenses ARO PNPLA3 To Madrigal To Expand MASH Options", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxOcm5lOTM5YUlicnViYUlERkxkMnZRTWl0d2F1ZWVWVTFOM0xRbjJsT0hDMVc2WnFwTTFJUW9DZWdWN1lOQkgxWFhBa1kwZHc3QzVVOTkxU09YMDV6cGIzOFA3YWlZLVk3ZjViQ2oySzlyRzE0S20zTWptY0k2Qy1UNEh5Z18xM3JmaW9hYzNVQS1janpYVFpQdWVqZjFzSTJlSkVNeE1xU191TE5UNkVHLWdsME56UFBYaDA1clZtTy1ldVl2TURPS0NscUVEQzduT2ZEOEYyNXpRZERzOGlpbkJldlJJVVNOVXp2Nm9CTG_SAfYBQVVfeXFMT1RaN2dkNE1nUlRxRTJ1ZlZpNldReG1hVHIydFJtdm1nVElWZXQ5cnp6TGxfeTJQb3VTMGRmbXJaOUczSnFnbEJObjdvNHRkR2NCV2ZWMThDLXo4RGVueVEyczVNeFk2ODZwSlRKWmFOekx0RkhpZG01RHFGdm5YSFZ2djF3NUF3S0VRZ0dCdE1rbU5tdHVaLTdJa0NjQVZuYWhQYmpHUml5cVc3MV95c0RHWmM1bHpZVUczalNELURDeWRfWFVlZ0ZsMFlocVhxZ0xOR0FhT1BtS3pVazltcFE3YWJZQ3lfZlVzYnZmWnVDa3Bzamt3?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead (NASDAQ: ARWR) director sells 2,970 shares under Rule 10b5-1 plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOeV94eUZ3eFVUMzVfUHY1Z1g0YW5RVUp6aDRScXliSVVqUTUwZERnbDg3VkNub3REX2dFZ0RFQ0V6Q3c1WkNRYVo5VWRzMzlJSG8yaWxERlNSbDFEZWcwdmFvNFE3bno2T2xvaWVlY2x3NXVOU1lqZ1B6Q3U1LWRGblNDZWxOWkEyYmxEaU5rSXIzZlZ0cy11VElsQ1p1b2tPaWprT3J6b2s0MUhZMG52Y2pqREtkZG5ub2lpaWxiREI?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] ARROWHEAD PHARMACEUTICALS, INC. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQNlRGVE13NG5mUUw3YzBTUDM0UF9HcEtlSFBOOHlEcGdXYXVmQmQzNnFxS0p2MzV4Yy14UldLVDBBMVFTeEtXQ3dNOVBlS3NzTTBaS1o1ZUFxdlZCZnVzVU1XR2dsd3QtYTFQOUZjVDFncktfRnRfaTh3clIxbVdZQm1WZUFuanFCMHBFNlQ2SkNSRHlCZlVCMk56aUpEaVRGczVXX2hEb2pXQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After Its Recent Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOaTUzV3F5MFJPU2owN1VFR0MtcHYzaHVrVjFhYmlnLTJvNFdCVkYzaHBSdXpycENXY1gxODVwY1EzTXpkekF3U2pYTmxxd2Z1Y2dFUlJobDVLTmZvVkVxRFNVSUZGRnZ3THBDclpwajg3UXNvNzhZdXpvZXVnR2xQdkdVTEVLMEU5WXpHNDNLcWs0Q2ZGLUpkbjk1SXI?oc=5", "source_name": "Market source", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Has Arrowhead Pharmaceuticals (ARWR) Run Too Far After Its 488% One Year Surge", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxQZmhJaUt5NFZnZEUweGZObl80UkozYUw0T2JfQzlTa2d1RE5icTMzYWYtV3VyZzR4OG5oRzlWN1NRMjRJSUVVSXBBTjdsVUs2NW5RMUgxbDVTc3JkYU45TVQyaWJmT2hnQUFrM3cxWHNVNHJkYi1tUzlVZ2lKczBqYzhqT1c2ZlNtRi1qUmc3a2R5eW52N3h5MTRPNGN3TzNsTm9rdHNjSkQ2Q0UwbUNYSFh0RFdoSTl5QmhEU2xnd3JpYWlDa2h4YXVHelhLcmJ1QU5kTHdQTVhsQkNfbUJuV29hWXc4RU9tNW9vZDd1aU_SAfYBQVVfeXFMTkpsaHNfTEhBZmdqdkhvVTZDVEh4cWpicU5XQ3hCRGRtYy13aVhzdkwxRDNZS3lPbHQ2MjNvQW1jWk92MTkyOHIzeGdpNVpCMDdBaXFiMjhKX25ZcC1Ib3RKUTdqenM4LW5xclVJU3p3ZUtGV3ZrSnNnYXY5YjdpRTRmMGxsZVVLbzNWcnp1c09OSGp6TDBDMVJhU3ZROU56Tzg4dmFtVm9iQVFFck1LOEVHTGk3X1lpbjc4N3lVV1BEMVVpalVUWHB5TEFYc0RxLXAxdjJSbDl6Y3ZaeXJ1YmdQUjVOM2NSd2t3bFRXVEF1akZmczJR?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Pharmaceuticals (ARWR) Q1 Profit Supports Bullish Narrative Despite High 54x P/E", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARROWHEAD PHARMACEUTICALS ($ARWR) Releases Q2 2026 Earnings | ARWR Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxPUnlCako4MUR3em9WdHg5Z2lzcUx2VlNXUVhHX1o2bGJmUHlFTXN5Y2JlSUN3em05STNkX0pINFpzZTlFanoxS244STRQS18xWkhVMGVPZGJLLWIyRFVCTzhDV09yRXg1dHk1NzFabVoxZ04waU96RDBBQlVrN0Q0WVY5cnNrZkcxbFVHakFXaDdFWjRqdVNV?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan Expects Arrowhead Pharma Stock to Rally on RNAi Portfolio Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNLU0zeUVEOWJDRjB2YS1wdkdKYU1Iczd3MUVNTGdoMGh6ZVQwRnp0N2JBYVVqZnRwaU1KQWN4VGozQWRyZldwTVRpdWZjbVlISE1za0FvNHo1MVhMQnVuNVBIWEZ1MEt2T3RjYnFDckw0REU5SXI1OWpMbHZkWjhhWW9aZFE0NnJST3VLNFVNaFhMaVV0d1ExTVFHd1RtNHUt?oc=5", "source_name": "TIKR.com", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "After 46% liver fat cut, Madrigal licenses Arrowhead MASH drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNOTFfWVJueGNSXzZ0SkZoTnV5a0FOVFJ5VG5HWWZtdjBaVXMzeWV4RTVzNUw0Z0dNZHpxUlVhNWdQZ0c2UVJRclRSMnhud20yNGM3UURZWTh6bkJUZjlNN05VZ2xZTTcwUERaQ1FfajF4S0pkQWs1dDZPX244cldGMlNkV3RYWkdiNEZmc1pXX2xYZW9aTFBzNExBNGN3VjgzVlJOb1ZfTjIteGRCamdDRmVFVmRWZnlDTmlJNWlB?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead lines up six May talks on obesity, liver fat and tau", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOSWdiamJmYVFna1pGTlZpakZQckxZMVp5c2VvWW5iZnFQYnZlbkN3cEhCVGpsSEhvY0p2VG9pcDdVdExTVi1vYmY1TTRiZnhZNEoyeVBISmg4V2VTNmVyaUkwNk5tX1RkaVFGNjFrMy1OSzVZS01qZGVPdjhyc19pSG56dGxYeGdqOUlrUmE0enlOdlpwa19odVBLbVJyTmN5T1FFVWlrdDFOX2NTQ2hhNVR0Sk5uVFE?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanguard Portfolio Management (NASDAQ: ARWR) reports 5.19% stake in Arrowhead", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNNjRGMk80YkRDQkU0cGpsUEF0SFFOM3RiZVhDMHRDV05XcDhmTzZDeldtOWVmMnM5VUctbXRiNzlNTXB1b2ZBVHE2SVNTSmRXaXV5TEExRFZaWnZ0cXYxb19tNklralFfUWZfOUZUM2JUYlh3Q005Y21IR0xDd3JRUHdkOXZKLXRrNFM2Uk5pYmM1UW9MT0VDY2Jra3pUd0FRU2ppa3psRTFEZzJtaHpnMXpiSndOci1rRTA5MjBPMDh6RC1hUVhyNHRhbw?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Pharmaceuticals: Transition Phase With Moderate Upside Ahead (NASDAQ:ARWR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQcS13SHFQbWtWUW50bDIxZDFGM01uUFdWc2VrQmZrVzZhdERSZmZhdGNGd0QxemM4OHh5cENoaGxqNnpxTEtsUF83cTUxaTl1VzZiV3daeUxlbUx1UU81T0V0NS1VRjBaOXhTdTN2MVNJeWh1RkRBRVBfYlZHN2lEMzlTZ1VWSXdyRTlHOEYwV3BpNGd2S1hWUTBVWTZsSGhQVlgyVURxaFZfT2c0Sm5z?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Pharmaceuticals Inc. (ARWR): Billionaire Ken Fisher Bets Big on Pharma", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxPUGg2VGk3aWxfc1pVMUR1ejJvcUFLa0lDYjVDRllwd2RUalRFVFBYTjNJUXJPMDVQLW91ZmdzR05DR01IQmoxakJOR3E4RER1RThpX2E4U2VRWmFPNGttR3NlODBwaUJPLVkzamtSNUxLQTR5WUV1aGgyQWx0eE9ka1NFNlJEWUdTaER6NE5UUl9IOWp0cHdR?oc=5", "source_name": "Market source", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Strong Earnings Are Of Good Quality", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Have Arrowhead Pharmaceuticals Insiders Been Selling Stock?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-03T08:00:00+00:00", "published_display": "03 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock Catapults 33% Though Its Price And Business Still Lag The Industry", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-02T08:00:00+00:00", "published_display": "02 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US FDA approves Arrowhead's genetic disorder drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPVGdKY0R4Y1BtY3JPYkxNUTdMZW01WF9rUVNId3dEbGxpWmF1ZXc5ZkJUOURUQTlXTEpaMDVoeXRnMzdNdnV6QUdHUnBUZmU3cTYtMUcwbmNqQXRFUVRqbGFDdzgzWTVPaXhoaHg1eFh2RFdmVVJ5VW9KZW42VGMtZUxTSUtqRHpMUVllM0VJOUhncTNERHo4THVHLTc4R3Yyc19aYi1rMkpmaVBIcTJTcnJaWTlSQVAzZ0p1Mw?oc=5", "source_name": "Reuters", "published_at": "2025-11-18T08:00:00+00:00", "published_display": "18 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Therapeutics Announces Advancement of siRNA Collaboration and Sale of Arrowhead Equity Investment", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxPemRoWUduMVZ2eGVVSUtnUjhQQUJfMm82WUtoQUJ4R2ZsMUtKbi1GdnlGbXpYaHgtaUhsOTBSVHRxLUdzM0xkRkN4d2pYMlNhUFdrcFdXUTB5UTB0ZERQY1A1VDI5VVdia2xHTEQ4MV9NeHQyd202alJOblBOUTZaLVYxbnE2cldvdm5hX2ZiMG90UVBXLWlTRVdaenpseTJEcmVSMnd5YUtlMnpsYVphZ2l1bEVVeGdjRGVCd1hVa2NUSW5Vczl4QjR2T09rRUJS?oc=5", "source_name": "Sarepta Therapeutics", "published_at": "2025-08-13T07:00:00+00:00", "published_display": "13 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 95, "total_relevant": 59, "sentiment_summary": {"positive": 21, "negative": 4, "neutral": 34, "score": 57, "total": 59, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 83, "events": [{"event": "general", "label": "Market update", "weight": 21.6, "count": 38}, {"event": "earnings", "label": "Earnings", "weight": 7.84, "count": 16}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 21, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 81.82, "latest_week": "2026-06-19", "one_week_move": 9.8, "four_week_move": 9.2, "twelve_week_move": 41.6, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.368133, "market_dynamics_buy_signal": false, "relative_strength": 37.126872, "fair_value_gap": 148.7, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 58.8274, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+9.8% over one week, +9.2% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 67, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 12}, {"label": "simplywall.st", "count": 11}, {"label": "Market source", "count": 8}, {"label": "Business Wire", "count": 5}, {"label": "Sahm", "count": 2}, {"label": "TradingKey", "count": 2}, {"label": "Quiver Quantitative", "count": 2}, {"label": "GuruFocus", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 52}, {"label": "Industry context", "count": 7}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 38}, {"label": "Earnings", "count": 16}, {"label": "Regulatory and legal", "count": 1}, {"label": "Balance sheet", "count": 1}, {"label": "Analyst action", "count": 1}, {"label": "Guidance", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "83/100 classification confidence."}, {"label": "Company focus", "value": "52", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+9.8% over one week, +9.2% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Arrowhead Pharmaceuticals (ARWR) Receives EU Approval for REDEMP"}], "updated_at": "2026-06-23T04:33:32.353719+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}